Sun et al. [22] showed that knockdown of Nrf2 in hepatocellular carcinoma cells enhanced the treatment efficacy of Erastin and Sorafenib both in vitro and in vivo. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.